{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:12:55Z","timestamp":1794276775676,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019203","name":"ImmunoGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ygyno.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:34:51Z","timestamp":1753223691000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer"],"prefix":"10.1016","volume":"200","author":[{"given":"Ursula A.","family":"Matulonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar M.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Method","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.06.016_bb0005","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ygyno.2025.06.016_bb0010","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.06.016_bb0015","doi-asserted-by":"crossref","first-page":"1258228","DOI":"10.3389\/fonc.2023.1258228","article-title":"Overcoming the challenges of drug development in platinum-resistant ovarian cancer","volume":"13","author":"Eskander","year":"2023","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2025.06.016_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.06.016_bb0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2025.06.016_bb0030","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.06.016_bb0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.06.016_bb0040","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2025.06.016_bb0045","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.016_bb0050","series-title":"ELAHERE (mirvetuximab soravtansine-gynx) [Prescribing Information]","year":"2024"},{"issue":"7","key":"10.1016\/j.ygyno.2025.06.016_bb0055","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-alpha (FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2025.06.016_bb0060","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"6a","key":"10.1016\/j.ygyno.2025.06.016_bb0065","first-page":"3567","article-title":"Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue","volume":"28","author":"Markert","year":"2008","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2025.06.016_bb0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2025.06.016_bb0075","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2025.06.016_bb0080","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2025.06.016_bb0085","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"17 suppl","key":"10.1016\/j.ygyno.2025.06.016_bb0090","volume":"41","author":"Moore","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.016_bb0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.06.016_bb0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.016_bb0105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2025.06.016_bb0110","first-page":"73","article-title":"Treatment of tumor cells with mirvetuximab soravtansine, a FR\u03b1-targeting antibody-drug conjugate (ADC), activates monocytes through Fc-Fc\u03b3R interaction and immunogenic cell death","volume":"4","author":"Skaletskyaya","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2025.06.016_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"issue":"9","key":"10.1016\/j.ygyno.2025.06.016_bb0120","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15","key":"10.1016\/j.ygyno.2025.06.016_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153849","article-title":"Tumor immune microenvironment in gynecologic cancers","volume":"15","author":"Margul","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2025.06.016_bb0130","doi-asserted-by":"crossref","first-page":"B21","DOI":"10.1158\/2326-6074.TUMIMM18-B21","article-title":"Synergistic antitumor immunity observed with combination FR\u03b1-targeting antibody-drug conjugate plus anti-PD-1 therapy is CD8+ cell dependent","volume":"8","author":"Gavrilescu","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2025.06.016_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2018.04.085","article-title":"Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients","volume":"149","author":"Matulonis","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.ygyno.2025.06.016_bb0140","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1200\/JCO.2017.35.15_suppl.5553","volume":"35","author":"O'Malley","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.ygyno.2025.06.016_bb0145","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1200\/JCO.2020.38.15_suppl.6004","article-title":"Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer","volume":"38","author":"Gilbert","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.06.016_bb0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O'Malley","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.016_bb0155","series-title":"VENTANA FOLR1 (FOLR1\u20132.1) RxDx Assay [Interpretation Guide for EOC]","year":"2022"},{"key":"10.1016\/j.ygyno.2025.06.016_bb0160","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2147\/OTT.S335936","article-title":"Immunotherapy in the treatment of platinum-resistant ovarian cancer: current perspectives","volume":"15","author":"Awada","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"13","key":"10.1016\/j.ygyno.2025.06.016_bb0165","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.016_bb0170","series-title":"KEYTRUDA (Pembrolizumab) [Prescribing Information]","year":"2024"},{"issue":"supplement 3","key":"10.1016\/j.ygyno.2025.06.016_bb0175","first-page":"A29","article-title":"#1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial","volume":"33","author":"Van Gorp","year":"2023","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"7","key":"10.1016\/j.ygyno.2025.06.016_bb0180","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:43:26Z","timestamp":1758915806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"alternative-id":["S0090825825008893"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}